Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in HFpEF with pulmonary hypertension
NL-OMON38270Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sildenafil in heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH), sponsored by University Medical Center Groningen. Started Oct 2011; status: active, not recruiting.
02
Drugs
sildenafil
03
Conditions
heart failure with preserved ejection fraction (HFpEF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NL-OMON38270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38270.